Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 33, 2018 - Issue 1
Submit an article Journal homepage
2,334
Views
21
CrossRef citations to date
0
Altmetric
Research Paper

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Sonali KurupCollege of Pharmacy, Roosevelt University, Schaumburg, IL, USA; Correspondence[email protected]
View further author information
,
Bradley McAllisterCollege of Pharmacy, Roosevelt University, Schaumburg, IL, USA; View further author information
,
Pavlina LiskovaCollege of Pharmacy, Roosevelt University, Schaumburg, IL, USA; View further author information
,
Trusha MistryCollege of Pharmacy, Roosevelt University, Schaumburg, IL, USA; View further author information
,
Anthony FanizzaDepartment of Chemistry, Harper College, Palatine, IL, USA; View further author information
,
Dan StanfordDepartment of Chemistry, Harper College, Palatine, IL, USA; View further author information
,
Jolanta SlawskaIII. Medical Department, Technische Universität München, Munich, Germany; View further author information
,
Ulrich KellerIII. Medical Department, Technische Universität München, Munich, Germany; ;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
&
Alexander HoelleinIII. Medical Department, Technische Universität München, Munich, Germany; View further author information
 show all
Pages 74-84 | Received 26 Apr 2017, Accepted 31 Aug 2017, Published online: 08 Nov 2017

References

  • Liao J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:409–24.
  • Kurup S, Dineley K, Malaiyandi L, et al. Drugs to treat head and neck cancers: mechanisms of action. In: Radosevich J, ed. Head & neck cancer: current perspectives, advances, and challenges. Springer: Dordrecht; 2013: 861–913.
  • Song Z, Ge Y, Wang C, et al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer. J Med Chem 2016;59:6580–94.
  • Chong C, Janne P. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389–400.
  • Mehra R, Serebriiskii I, Burtness B, et al. Aurora kinases in head and neck cancer. Lancet Oncol 2013;14:e425–35.
  • Hoellein A, Pickhard A, von Keitz F, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011;2:599–609.
  • Astsaturov I, Ratushny V, Sukhanova A, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010;3:ra67.
  • Chen J, Lu H, Zhou W, et al. AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827. Oncol Rep 2015;33:1860–6.
  • Zhang J, Pan X, Astsaturov IA, et al. Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2011;29:e13038.
  • Knight Z, Lin H, Shokat K. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130–7.
  • Zhu W, Chen H, Wang Y, et al. Design, synthesis, and pharmacological evaluation of novel multisubstituted pyridin-3-amine derivatives as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer. J Med Chem 2017;60:6018–35.
  • Wood E, Truesdale A, McDonald O, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652–9.
  • Gangjee A, Kurup S, Ihnat M, et al. N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. Bioorg Med Chem 2012;20:910–14.
  • Gangjee A, Kurup S, Ihnat M, et al. Synthesis and biological activity of N4-phenylsubstituted-6-(2,4-dichlorophenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem 2010;18:3575–87.
  • Grotzfeld R, Patel H, Mehta S, et al. Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases. US 2005/0153989 A1 20050714.
  • Traxler P, Guido B, Karl-Diether W, Joerg F. Preparation of 7H-pyrrolo[2,3-d]pyrimidines as tyrosine protein kinase inhibitors. PCT Int Appl 1997; WO 9702266 A1.
  • Gangjee A, Zaware N, Raghavan S, et al. N4-(3-Bromophenyl)-7-(substitutedbenzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis and in vivo evaluation. Bioorg Med Chem 2012;20:2444–54.
  • Cheng H, Nair S, Murray B, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants. J Med Chem 2016;59:2005–24.
  • Le Brazidec J, Pasis A, Tam B, et al. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as aurora kinase inhibitors. Bioorg Med Chem Lett 2012;22:4033–7.
  • Kawakita Y, Seto M, Ohashi T, et al. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorg Med Chem 2013;21:2250–61.
  • Bavetsias V, Faisal A, Crumpler S, et al. Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells. J Med Chem 2013;56:9122–35.
  • Molecular Operating Environment (MOE 2016.08), Chemical Computing Group, Inc, 1255 University St., Suite 1600, Quebec, Canada, H3B3X3; 2017.
  • Zegzouti H, Zdanovskaia M, Hsiao K, Goueli S. ADP-Glo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol 2009;7:560–72.
  • Fabian M, Biggs W, Treiber D, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329–36.
  • Addepalli M, Ray K, Kumar B, et al. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther 2010;17:352–9.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.